MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
S PignataD CalifanoD LorussoL ArenareM BartolettiU De GiorgiC AndreettaC PisanoG ScambiaD LombardiA FarolfiS CinieriA PassarelliV SalutariC De AngelisC MignognaD PrioloE D CapoluongoS TamberiG L ScaglioneV ArcangeliR De CecioG ScognamiglioF GrecoA SpinaM TurinettoD RussoV CarboneC CasartelliC SchettinoF PerronePublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)
The MITO END-3 trial results suggest that TP53 mutation is associated with a poor effect of avelumab, while mutations of PTEN and ARID1A are related to a positive effect of the drug in patients with advanced EC.